Whalesbook
Skybiotech Healthcare Ltd has officially confirmed it does not meet the criteria for a 'Large Corporate' under SEBI regulations. The company stated this status as of March 31, 2026, in a filing to stock exchanges on April 30, 2026. This confirmation exempts Skybiotech from specific mandatory debt fundraising obligations required for large entities.
The clarification provides significant regulatory relief. SEBI's 'Large Corporate' framework mandates companies to raise a portion of their funding through debt securities. By not qualifying, Skybiotech avoids these compliance requirements, associated disclosures, and potential penalties, granting it greater flexibility in its financing strategy.
SEBI introduced the 'Large Corporate' framework to bolster the corporate debt market. Typically, a 'Large Corporate' is a listed entity with outstanding long-term borrowing of at least INR 1000 crores and a credit rating of 'AA' or above, following a revised framework implemented around 2023. Companies classified as such must raise a minimum of 25% of their incremental borrowings via debt securities. Skybiotech had previously clarified its non-applicability to this category in April 2025.
Despite the regulatory clarity, Skybiotech Healthcare faces significant financial challenges. The company holds a 'Strong Sell' rating from MarketsMojo as of April 16, 2026. It has struggled with operating losses and weak long-term fundamental strength, reporting stagnant net sales over the past five years. As of April 16, 2026, Skybiotech reported a negative EBITDA of ₹-2.26 crores and a Debt to EBITDA ratio of -999,999 times. This backdrop is reflected in its stock performance, which has delivered a -33.19% return over the past year.
Other companies, such as GHCL Limited, have also issued similar clarifications, confirming they do not meet the 'Large Corporate' criteria to avoid SEBI's debt fundraising mandates.
Investors will be watching Skybiotech's future fund-raising plans and how it utilizes its clarified regulatory status. Key areas to monitor include any potential shifts in SEBI's 'Large Corporate' definition and the company's ability to improve its fundamental financial health and operational performance.